-
Cordis shares positive study results from multiple drug-eluting balloon studies
25 Apr 2025 15:56 GMT
… studies showcase drug elution, done better – sustained sirolimus delivery results … Cordis’ SELUTION SFA Japan trial took place in a … in leave-nothing-behind treatment strategies. These 3-year … Hochsauerland, Germany, chief medical officer and director of …
-
Cordis Announces Positive Results From Two Major Studies Demonstrating Durable Efficacy Of SELUTION SLRTM Drug-Eluting Balloon In Complex Peripheral Artery Disease Patients
25 Apr 2025 02:44 GMT
… Results – SELUTION SFA Japan Trial: First Sirolimus DEB with Proven Long-Term … evolution in Leave-Nothing-Behind treatment strategies. These 3-year outcomes … Medical Officer at Cordis. "The SELUTION SLRTM studies showcase drug elution …
-
First drug OK'd for most common heart condition in cats
25 Apr 2025 00:38 GMT
… Rapamycin, also known as sirolimus, already is used off- … Felycin contains rapamycin, a medication with a variety of applications … Miller followed the Felycin trial study with interest. Once … for treatment. Extralabel use of conditionally approved drugs is …
-
R3 Vascular reports first patient treated in next-gen drug-eluting scaffold study
22 Apr 2025 20:59 GMT
… ELITE-BTK pivotal trial of its drug-eluting bioresorbable scaffold … Cornell Medicine treated the first patient. The trial evaluates … anti-proliferative results of sirolimus while disappearing over … treatment of the first patient in our ELITE-BTK pivotal trial …
-
Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy
22 Apr 2025 11:00 GMT
… U.S. Food and Drug Administration (“FDA”) has granted Breakthrough Device … TPT”) under the Center for Medicare & Medicaid Services (“CMS”) programs. These … developing the Virtue® Sirolimus AngioInfusion™ Balloon (SAB) for the treatment of atherosclerotic …
-
R3 Vascular Announces First Patient Treated in ELITE-BTK Pivotal Trial for Below-the-Knee PAD Using MAGNITUDE® Drug Eluting Bioresorbable Scaffold
22 Apr 2025 10:00 GMT
… Vascular Inc., a medical device company dedicated to … market application with the FDA.” Dr. DeRubertis … trial will reveal MAGNITUDE’s unique potential to further advance treatment … of fully bioresorbable drug eluting sirolimus coated vascular scaffolds. …
-
FDA Grants Breakthrough Therapy Designation to AMT-130 to Treat Huntington Disease
21 Apr 2025 18:11 GMT
… 130 (uniQuire) for the treatment of Huntington disease. Previously, … regenerative medicine advanced therapy designation and orphan drug designation … 1/2 clinical trials—a proof-of-concept … that consists of dexamethasone, sirolimus, and rituximab. Cohorts 1 …
-
A Giant Step in the Right Direction: One of Trump's Latest Executive Orders Will Help Lower Drug Costs
19 Apr 2025 10:24 GMT
… ;HMO insurances and require drugs such as Tacrolimus, Sirolimus, or even Mycophenolate … depends on the number of pills and the plan.
Meanwhile, at … to their PBM-owned pharmacy, Medicare/Medicaid reimburse all pharmacies.
I have …
-
Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 8-9 April 2025
11 Apr 2025 16:16 GMT
… the progeny of the vaccinated chickens to reduce … initial marketing authorisation for Sirolimus TriviumVet. More information … immunological and two concerned pharmaceutical products. The target … about the above-mentioned medicines (including their full …
-
Safety and Efficacy of a Paclitaxel-Coated Balloon for the Treatment of Symptomatic Patients with Long Superficial Femoral Artery Disease
10 Apr 2025 13:22 GMT
… treating femoropopliteal artery disease. Ongoing trials aim to compare its performance … , such as the SIRONA trial, are comparing sirolimus-coated balloons to established … , Brodmann M, et al. Drug-coated balloon treatment for femoropopliteal artery disease …
About
© 1995-2025